All In Biotech

Drug Trial Radar · NCT07140783

OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-MASKED STUDY OF THE SAFETY AND EFFICACY OF POS (0.75% PHENTOLAMINE OPHTHALMIC SOLUTION) IN PARTICIPANTS WITH PREVIOUS KERATOREFRACTIVE SURGERY WITH DECREASED VISUAL ACUITY UNDER MESOPIC CONDITIONS

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 580 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

580

Planned (sponsor's estimate)

Start

Sep 2, 2025

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
First posted
Aug 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if Phentolamine Ophthalmic Solution works to treat adults that have had keratorefractive surgery and have decreased visual acuity under mesopic conditions. It will also learn about the safety of Phentolamine Ophthalmic Solution. The main questions it aims to answer are: Researchers will compare Phentolamine Ophthalmic Solution to a placebo (a look-alike substance that contains no drug) to see if Phentolamine Ophthalmic Solution works to improve vision in low light conditions. Participants will: Take Phentolamine Ophthalmic Solution or a placebo drop every day for 2 weeks Visit the clinic once every week for 2 weeks for checkups and tests Keep a diary of when they instill the study medication each evening

Conditions

  • Vision Loss Night
  • Vision Disorders

Interventions

  • 0.75% Phentolamine Ophthalmic SolutionDrug

    Once daily dosing

  • PlaceboDrug

    Once daily dosing

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of participants with >= 15 ETDRS letters (>= 3 lines) improvement in the study eye in mLCVA compared to Baseline (Day1 pre-dose) at Day 15Time frame: Day 15

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Eye Care

    Chandler, Arizona · Recruiting

  • Eye Doctors of Arizona

    Phoenix, Arizona · Recruiting

  • MRB Eye Care Consultants

    Scottsdale, Arizona · Recruiting

  • Global Research Management

    Glendale, California · Recruiting

  • Gordon Schanzlin New Vision

    La Jolla, California · Recruiting

  • Eye Research Foundation

    Newport Beach, California · Recruiting

  • California Eye Specialists Medical Group

    Pasadena, California · Recruiting

  • NVISION Clinical Research

    San Diego, California · Recruiting

  • Scripps Poway Eyecare and Optometry

    San Diego, California · Recruiting

  • Wolsten and Goldberg Eye Assoc.

    Torrance, California · Recruiting

  • Segal Drug Trials

    Delray Beach, Florida · Recruiting

  • Wyse Eyecare

    Northbrook, Illinois · Recruiting

  • Virdi Eye Clinic

    Rock Island, Illinois · Recruiting

  • Kannarr Eye Care

    Pittsburg, Kansas · Recruiting

  • Northeast Eye Research Associates

    Woburn, Massachusetts · Recruiting

  • Oculus Research

    Garner, North Carolina · Recruiting

  • Scott & Christie EyeCare Associates

    Cranberry Township, Pennsylvania · Recruiting

  • West Bay Eye Assoc.

    Warwick, Rhode Island · Recruiting

  • Zillan Clinical Research

    Houston, Texas · Recruiting

  • Hoopes Vision

    Draper, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.